

**دور الفلورين ف.د.ج باستعمال البوزيترون المقطعي في تحديد درجة المرض
و متابعة أورام الثدي**

مقدمة من

الطبيبة / ميرة عبدالله راشد المعلا

توطئة للحصول على درجة الماجستير في الطب النووي

تحت اشراف

أ.د حسنة محمد مصطفى

أستاذ الطب النووي

كلية الطب – جامعة القاهرة

أ.م.د. شاهنדה صبري سالم

أستاذ مساعد الطب النووي

كلية الطب – جامعة القاهرة

٢٠٠٩

**The Role of F-18 FDG-PET and PET/CT in Staging and
Follow Up Breast Cancer Patients**

Assay

**Submitted for partial fulfillment of
Master degree in Nuclear Medicine
Presented by**

**Mira Abdulla Rashid Al Mualla
(M.B.B.Ch; in Medicine)**

Under supervision of

Prof. Dr.Hosna Moustafa

**Prof. of nuclear medicine
Faculty of Medicine, Cairo University**

Ass. Prof Dr Shahenda Sabry Salem

**Assistant Professor Nuclear Medicine
Faculty of Medicine, Cairo University**

Faculty of Medicine, Cairo University

Department of Nuclear Medicine

2009

CONTENTS:

1. List of figures	i
2. List of tables	iii
3. List of abbreviations	iv
4. Introduction and aim of work	1
5. Anatomy of the breast	4
6. Pathology of breast cancer	13
7. Principles of Positron Emission Tomography	32
8. PET/CT	48
9. Technique of PET and PET/C in breast imaging	65
10. PET and PET/CT findings in breast cancer	84
11. Other Imaging modalities used in Breast Cancer	102
12. Discussion and Conclusion	122
13. Summary	129
14. References	131
15. Arabic summary	147

Introduction

Breast cancer has become a major health problem affecting each twelfth of all women during their lifetime; it is now the most frequently occurring malignant disease in women. Breast cancer can occur in men, although the incidence is much lower, amounting to around 1% of all breast cancers.

Overall, the incidence of breast cancer rises with age, increasing rapidly during the fourth decade of life and continuing to increase thereafter, but more slowly in the fifth, sixth and seventh decades. The effect of family history on breast cancer risk believed to be due primarily to genetic factors. (*Jemal et al., 2004*)

Mammography and ultrasound considered as the main diagnostic imaging tools for the diagnosis of primary breast cancer. (*Samson et al, 2002*)

FDG-PET may be useful in the noninvasive characterization of the indeterminate lesions by providing metabolic information. FDG-PET is superior in detecting tumor-involved lymph nodes, particularly those that are normal in size radiologically and is superior in characterizing enlarged lymph nodes as positive or negative. (*Avril et al, 2007*)

FDG-PET scanning has been demonstrated to be accurate in the diagnosis of metastatic and recurrent disease not recognized by conventional imaging methods. (*Jadvar et al, 2003*)

FDG-PET has been compared with bone scan in the detection of osseous metastases. PET and bone scan appear to offer similar sensitivity in this regard, but PET provides a specificity advantage over bone scan. (*Kao,2000*)

An integrated PET/CT system offers several advantages, by allowing a fast and relatively low-noise transmission scan, a short scanning time, and in achieving additional anatomical and diagnostic information. In breast cancer, an increase in diagnostic accuracy is expected, for both primary staging and restaging. (*Rosen et al, 2007*)

Aim of Work

The purpose of the work is to assess the implementation of FDG-PET and PET/CT in clinical routine and evaluate their role in breast cancer primary staging, restaging and therapy monitoring.

List of tables

Table Number	Title	Page
2-1	Non-invasive carcinoma of the breast	18
2-2	Invasive carcinomas of the breast	18
2-3	TNM staging system for breast cancer.	29-31
2-4	TNM stage grouping for breast cancer.	31
4-1	Comparison between acquisitions steps in combined and separate CT and PET.	56

List of abbreviations

%	percentage
~	Approximately
<	Less than
>	More than
¹¹ C	Carbon
¹³ N	Nitrogen
¹⁵ O	Oxygen
¹⁸ O	Oxygen
¹⁸ F	Radioactive Fluorine
¹⁸ F-FDG	2-{ Flourine-18} Flouro-2-deoxy-D-glucose
⁶⁸ Ge	germanium-68
2D	Two Dimensional
3D	Three Dimensional
ACF	Attenuation correction factors
ADC	Apparent Diffusion Coefficient
AJCC	American Joint Committee on Cancer
AND	Axillary node dissection
ALND	axillary lymph node dissection
Au198	Radioactive isotope
BGO	Bismuth germinate
BRCA	Gene breast cancer
BSA	Body surface area
cc	Milliliter
CIS	Carcinoma in situ
cm	centimeter

CT	Computerized tomography
CTAC	Computerized tomography attenuation corrected
DCIS	Ductal carcinoma in situ
DTPA	Diethylene triamine penta acetic acid
e-	Electron
e.g	Example
e+	Positron
EIC	Extensive intraductal component
ER	Estrogen Receptor
FDA	Food and Drug Administration
FDG	Fluorodeoxyglucose
FES	Fluoroestradiol
FLT	fluorothymidine
FOV	Field Of View
FWHM	Full width at half maximum
g	gram
Gd	Gadolinium
Glut	glucose transporter
GSO	Gadolinium oxyorthosilicate
h	Hour
HER-2/neu	Human epidermal growth factor receptor gene
HGF	Hematopoietic growth factor
i.e	Example
I.V	intra venous
IDC	Invasive ductal carcinoma
ILC	Invasive lobular carcinoma
KeV	Kilo electron Volt

keV/c ²	Kilo electron Volt ,c is the velocity of light
Kg	Kilogram
Km	Kilometer
LCIS	Lobular carcinoma in situ
LOR	Line of response
LSO	Lutetium oxyorthosilicate
mA	Milliamperage
MBq	Mega Becquerel
mCi	milli curie
MDP	Methylene diphosphonate
Mg/dl	A measure of concentration (mass per unit volume)using milligrams per decilitre (One-tenth of a litre)
min	minute
MIP	Maximum intensity projection
mm	Millimeter
mm ² /s	Millimeter square per second
MRI	Magnetic resonance imaging
mRNA	messenger ribonucleic acid
MRS	Magnetic Resonance Spectroscopy
mSv	Millisevert
NaI (TL)	Thallium-activated sodium iodide crystals
NPV	Negative predictive value
P53	Tumor protein 53
PEM	Positron Emission Mammography
PET	Positron Emission Tomography
PPV	Positive predictive value

PVE	Partial volume effect
ROI	Region of interest
sec	Second
Sesta MIBI	Sesta methoxy isobutyl isonitrile
SLN	Sentinel lymph node
SN	Sentinal Node
SNB	Sentinal Node biopsy
SPECT	Single Photon Emission Computerized Tomography
SUV	Standardized Uptake Value
Tc 99 m	Technetium 99 m
TDLU	Terminal ductal-lobular unit
TNM	Tumor, nodal metastases, distant metastases
US	Ultrasound
Ve	electron neutrino
WB	Whole body
Y	Photon

List of figures

Figure Number	Title	Page
1-1	Normal breast with an enlarged diagram of microscopic structure of a breast tissue.	7
1-2	Lymph node areas adjacent to breast area.	9
2-1	Intraductal carcinoma.	19
2-2	Lobular carcinoma in situ (LCIS)	20
2-3	Invasive duct carcinoma.	22
2-4	Infiltrating lobular carcinoma.	23
2-5	Paget's disease of the nipple.	26
3-1	Uptake of FDG.	35
3-2	The principles of PET imaging shown schematically.	36
3-3	Annihilation reaction.	37
3-4	Coincidence imaging.	39
3-5	Scattered photons and random coincidence.	40
3-6	PVE spilling in and out	43
3-7	Comparison of early and delayed FDG-PET images.	46
4-1	PET/CT Scanner.	50
4-2	Flowchart of typical PET/CT Operation.	52
4-3	Standard FDG-PET/CT imaging protocol.	54
4-4	Streak artifacts	58
4-5	Image artifacts	60
4-6	Respiration-induced artifacts	63
5-1	PEM detector	72
5-2	Difference in image resolution between WB PET imaging and PEM	73
5-3	Normal distribution of FDG.	75
5-4	Symmetric salivary gland uptake.	76
5-5	Cardiac FDG uptake.	76
5-6	Renal activity.	78
5-7	Muscle uptake of FDG.	80
5-8	FDG PET in Adipose tissue.	81
5-9	FDG PET in normal Thymus	81
5-10	Bone marrow uptake	82
5-11	Spleen uptake	83
6-1	Incidental left breast cancer discovered by FDG	87
6-2	A case of left breast cancer discovered by FDG PET	87
6-3	PET/CT localizing Invasive breast cancer	88
6-4	PEM scan of right breast cancer	89
6-5	A case of Axillary lymph node metastasis	90

6-6	PET images demonstrate the primary tumor and multiple positive axillary nodes	92
6-7	A case of Bone metastases from breast cancer Comparison between bone scan and PET	94
6-8	Bone metastases post therapy follow up by both bone scan and PET/CT	95
6-9	¹⁸ F-FDG-PET projection image of a patient with breast cancer metastatic to the right lung.	96
6-10	Combined CT & PET data shows a patient with locoregional recurrence of breast carcinoma.	98
6-11	PET in evaluating response to therapy in breast cancer.	100
6-12	PET/CT follow up response of therapy	101
7-1	Scintimammography done for female presented with bilateral palpable masses	103
7-2	Illustration of sentinel lymph node biopsy	106
7-3	A case of invasive ductal carcinoma had digital mammogram	113
7-4	Breast ultrasonography	114
7-5	MR scanning of a patient using a dedicated breast coil	117
7-6	Breast MRI showing a malignant lesion in the right breast.	120

Discussion and Conclusion

Discussion and Conclusion

Breast cancer is the most common malignant tumor among women. It is the leading cause of cancer death in women after lung cancer. (*Schwartz et al, 1999*)

Detection and treatment of breast cancer at an early stage is the only method with proven potential for lowering the death rate from the disease. Axillary lymph node involvement is the most important prognostic factor for determining survival from breast cancer. (*Alder et al, 1997*)

Imaging in breast cancer has an important role to play at all stages of the disease from initial screening of women who are unaware they may have the disease, to symptomatic women who present with a lump or other symptom of breast disease, to those with established breast cancer.

After confirming the diagnosis, imaging has a vital role in staging the disease and assessing response to treatment. (*Buscombe et al, 2004*)

Accurate staging is critical for therapeutic planning. Unfortunately, previous surgery and radiation therapy can result in scarring that can complicate the evaluation for locoregional recurrence of breast cancer- particularly in the axillary region. (*Schwartz et al, 1999*)

Mammography is the primary screening technique for breast cancer because of its relatively low cost, high spatial resolution (0.1 mm), and ability to observe tumors in early stage. (*Homer, 1984*)